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Abstract 
Context: Standard glucocorticoid therapy in congenital adrenal hyperplasia (CAH) 
regularly fails to control androgen excess, causing glucocorticoid overexposure and 
poor health outcomes.
Objective: We investigated whether modified-release hydrocortisone (MR-HC), which 
mimics physiologic cortisol secretion, could improve disease control.
Methods: A 6-month, randomized, phase 3 study was conducted of MR-HC vs standard 
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were change in 24-hour SD score (SDS) of androgen precursor 17-hydroxyprogesterone 
(17OHP) for phase 3, and efficacy, safety and tolerability of MR-HC for the extension 
study.
Results: The phase 3 study recruited 122 adult CAH patients. Although the study failed 
its primary outcome at 6 months, there was evidence of better biochemical control on 
MR-HC, with lower 17OHP SDS at 4 (P = .007) and 12 (P = .019) weeks, and between 
07:00h to 15:00h (P = .044) at 6  months. The percentage of patients with controlled 
09:00h serum 17OHP (< 1200 ng/dL) was 52% at baseline, at 6 months 91% for MR-HC 
and 71% for standard therapy (P = .002), and 80% for MR-HC at 18 months’ extension. 
The median daily hydrocortisone dose was 25 mg at baseline, at 6 months 31 mg for 
standard therapy, and 30  mg for MR-HC, and after 18  months 20  mg MR-HC. Three 
adrenal crises occurred in phase 3, none on MR-HC and 4 in the extension study. MR-HC 
resulted in patient-reported benefit including menses restoration in 8 patients (1 on 
standard therapy), and 3 patient and 4 partner pregnancies (none on standard therapy).
Conclusion: MR-HC improved biochemical disease control in adults with reduction in 
steroid dose over time and patient-reported benefit.
Key Words: congenital adrenal hyperplasia, 21-hydroxylase deficiency, glucocorticoid, hydrocortisone, 
adrenal insufficiency
Classic congenital adrenal hyperplasia, due to 21-hydroxylase 
deficiency (21-OHD-CAH), is a genetic disorder of 
steroidogenesis affecting approximately 1:15 000 live births 
(1). Lack of 21-hydroxylase causes cortisol deficiency and 
a counter-regulatory increase in pituitary adrenocortico-
tropin (ACTH) secretion, which drives overproduction of 
adrenal androgens, and adrenal hyperplasia. Patients with 
21-OHD-CAH have 2 major problems: adrenal insuffi-
ciency and androgen excess. Adrenal insufficiency causes 
life-threatening adrenal crises (1-3), while androgen excess 
causes atypical genitalia in 46,XX neonates, promotes ab-
normal growth, short stature, and precocious puberty, and in 
adulthood, virilization of women and infertility in both sexes 
(4). Treatment aims to replace cortisol, and, where neces-
sary, aldosterone. Supraphysiologic doses of glucocorticoids 
are typically needed to suppress ACTH and adrenal andro-
gens. Management involves balancing glucocorticoid doses 
to avoid both glucocorticoid deficiency, risking adrenal crisis, 
and iatrogenic glucocorticoid excess, leading to short stature, 
obesity, hypertension, osteoporosis, and an adverse metabolic 
profile (1-3, 5-7). Patients with 21-OHD-CAH have increased 
mortality (8, 9) and poor health outcomes (10, 11) because 
current therapy fails to control adrenal androgen excess re-
sulting in glucocorticoid overtreatment (5, 12).
Cortisol has a circadian rhythm with a nadir on going 
to sleep, increasing during early morning hours, peaking on 
waking, then decreasing through the day (13). In 21-OHD-
CAH, absent cortisol overnight results in excess early-
morning ACTH, which in turn drives excess generation 
of adrenal androgens. The adrenal androgen precursors, 
17-hydroxyprogesterone (17OHP) and androstenedione are 
used for monitoring. Current glucocorticoids used in the treat-
ment of 21-OHD-CAH are immediate-release preparations 
such as hydrocortisone, prednisolone, prednisone, and dexa-
methasone, which fail to mimic the early-morning cortisol 
rise (10, 11). There is consensus that hydrocortisone should 
be used in children to avoid risk of growth suppression with 
long-acting glucocorticoids (14); however, in adults, there is 
no agreement on which glucocorticoid to use. Patients often 
take glucocorticoids later in the evening to achieve biochemical 
control, when cortisol is normally low, resulting in metabolic-
ally adverse consequences (15). Despite different treatment re-
gimens, optimal biochemical control, defined as 17OHP below 
3 times the upper limit of normal (< 1200 ng/mL, 36 nmol/L) 
and androstenedione within the reference range, is achieved in 
only approximately 40% of patients (10, 11).
Hydrocortisone infusions mimicking the cortisol cir-
cadian rhythm have demonstrated improved biochemical 
control of 21-OHD-CAH (16, 17). A  modified-release 
formulation of hydrocortisone (MR-HC), with a delayed-
release action, given twice daily, simulates the overnight in-
crease of cortisol (18, 19), and improved 21-OHD-CAH 
disease control in a phase 2 study (19). We now report find-
ings from a phase 3 study of MR-HC vs standard gluco-
corticoid therapy followed by a single-arm efficacy and 
safety extension study in adults with 21-OHD-CAH.
Materials and Methods
Patients
Patients were recruited from 10 centers (7 countries) 
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21-OHD-CAH diagnosed in childhood, adequate min-
eralocorticoid replacement with renin less than 2 times the 
upper limit of normal, and were on stable glucocorticoid 
therapy over the preceding 6  months. Exclusion criteria 
included use of medication interfering with glucocorticoid 
metabolism, bilateral adrenalectomy, and night-shift work. 
The study protocols for the phase 3 extension study were 
approved by local ethics/institutional review boards and 
the Medicines and Healthcare Products Regulatory Agency 
(NCT03062280, Eudract 2015-005448-32). The trials 
were performed in accordance with the principles of the 
Declaration of Helsinki.
Trial Design
Patients, stratified by baseline glucocorticoid treatment 
(Table 1), were randomly assigned by an interactive web 
response system to receive MR-HC (Chronocort Diurnal 
Ltd UK) or to continue on standard therapy and after 
6  months were offered MR-HC in the extension study. 
MR-HC was prescribed as 5-, 10-, or 20-mg capsules, and 
the initial dose was the hydrocortisone dose equivalent 
to their baseline therapy, with approximately one-third of 
the daily dose taken at 07:00h and two-thirds of the daily 
dose taken at 23:00h. At 4 and 12 weeks, dose titrations 
were made for both treatment groups, using identical 
rules, following centralized advice by 2 independent phys-
icians blinded to all data except 24-hour hormone pro-
files and an investigator-completed adrenal insufficiency 
checklist. The blinded titrators considered morning and/
or evening dose adjustments of either MR-HC or standard 
glucocorticoid using 17OHP/androstenedione measure-
ments from the 24-hour profile and adrenal insufficiency 
symptom questionnaire (Table 2) results using the fol-
lowing algorithm:
 •  the 5 samples between 01:00 to 09:00h were considered 
to reflect glucocorticoids given in the evening/night 
time;
 •  the 5 samples between 11:00 and 19:00h to reflect 
glucocorticoids given in the morning;
 •  if 3 or more of these 5 samples were out of range, 
dose adjustments would be made, unless the adrenal 
insufficiency symptom questionnaire was in conflict 
with the biochemical findings; and
 •  if 17OHP and androstenedione were inconsistent then 
the androstenedione results were to take precedence.
Target ranges for titration were the optimal range for 
17OHP and reference range for androstenedione as follows:
 •  17OHP 40 to 1200 ng/dL (range, 1.2-36.4 nmol/L);
 •  androstenedione (males) 40 to 150 ng/dL (range, 1.4-
5.2 nmol/L); and 
 •  androstenedione (females) 30 to 200  ng/dL (range, 
1.0-7.0 nmol/L).
Local investigators and patients were aware of the trial-
group assignment but were otherwise blinded. After 
6 months, patients who had enrolled in the phase 3 and the 
previous phase 2 studies were invited to enroll in the exten-
sion study. The initial dose of MR-HC was the hydrocor-
tisone dose equivalent to their dose at time of enrollment 
in the extension study. Dose titration was performed by 
the local investigators according to hormone results and 
symptoms of overreplacement or underreplacement. 
Table 1. Patient baseline characteristics






No. 61 61 91
Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)
Female sex, No. (%) 42 (68.9) 36 (59) 62 (68.1)
Salt-wasting, No. (%) 49 (80) 51 (84) 77(85)
BMI, median (range) 27.8 (18.0-43.7) 27.0 (19.7-36.8) 28.3 (18.0-43.7)
Fludrocortisone use, No. (%) 52 (85) 52 (85) 77 (85)
Fludrocortisone mcg/d, median (range) 100 (25-400) 100 (25-400) 100 (25-500)
Good disease control, No. (%)a,b 20 (37.7) 32 (61.5) 52 (50.0)
Prestudy glucocorticoid treatment  
Hydrocortisone, No. (%) 36 (59.0) 39 (63.9) –
Prednisolone, No. (%) 21 (34.4) 22 (36.1) –
Dexamethasone, No. (%) 5 (8.2) 5 (8.2) –
Prednisone, No. (%) 3 (4.9) 2 (3.3) –
Abbreviation: BMI, body mass index.
aGood disease control defined as 09:00-hour 17-hydroxyprogesterone less than 1200 ng/dL.
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Hydrocortisone stress dosing and fludrocortisone dose ad-
justment occurred as medically indicated (20).
Trial Procedures
In the phase  3 study, 17OHP and androstenedione were 
measured at baseline, 4, 12, and 24 weeks every 2 hours 
from 15:00h to 15:00h, and in the extension study, blood 
was drawn at 09:00h and 13:00h. Hormones were meas-
ured by high-performance liquid chromatography–tandem 
mass spectrometry (Q2 Solutions). Additional assessments 
included body composition, dual-energy x-ray absorpti-
ometry (DEXA) scanning, metabolic bloodwork (C-terminal 
cross-link telopeptide, fasting osteocalcin, high- sensitivity 
C-reactive protein, fasting glucose, fasting insulin, glycated 
hemoglobin A
1c
, plasma renin activity, total testosterone), 
and quality of life (QoL) assessments (Medical Outcome 
Short Form Health Survey Form 36 [SF-36], Global Fatigue 
Index, Standardized Health Questionnaire [EQ-5D]).
Outcome Measures
The primary outcome in the phase 3 study was the change 
from baseline to 24 weeks in the mean of the 24-hour 
17OHP SD scores (SDS). Natural log transformation was 
performed to approximate a normal distribution. For each 
2-hourly value of log 17OHP, the number of SDs from the 
midpoint of the natural logarithm of the reference range 
(males 40-220 ng/dL [1.2-6.7nmol/L], females 40-285 ng/
dL [1.2-8.6  nmol/L]) was calculated, unsigned to pro-
vide equal weight to values above or below the midpoint. 
Secondary outcomes included serum androstenedione, 
safety (specifically stress dosing and adrenal crises) (21), 
and changes in weight, body mass index, waist circumfer-
ence, body composition, and blood pressure. Exploratory 
end points included the primary outcome at 4 and 12 
weeks. Post hoc analyses included percentage of patients 
with good disease control defined as 09:00h for 17OHP 
less than 1200 ng/dL (< 36 nmol/L) and for androstene-
dione below the reference range upper limit as previously 
defined (10, 11); areas under the curve (AUCs) of 17OHP 
and androstenedione; and 17OHP variability expressed 
as the ratio of arithmetic range of concentrations over 24 
hours at 24 weeks to baseline. In the extension study, the 
primary end point was MR-HC safety assessed longitudin-
ally using signs and symptoms of adrenal insufficiency or 
overtreatment; use of sick day rules; and adverse events 
including adrenal crises. The secondary end points in-
cluded MR-HC long-term efficacy measurements such as 
daily dose of hydrocortisone and disease control assessed 
Table 2. Adrenal insufficiency checklist
This questionnaire should be used to determine whether symptoms of underreplacement or overreplacement of 
glucocorticoids have occurred in the preceding 4 weeks. Please ask participant: Have you experienced any of the following 
symptoms more than once per week in the last 4 weeks? 
Date of assessment (mm/dd/yyyy).
Symptoms Y/N If Yes, do you believe this to be related  
to under or over replacement of  
glucocorticoid? Please state over/under
Any clinically significant 
findings? Y/N
Sudden weight loss    
Sudden weight gain    
Lack of appetite    
Nausea    
Vomiting    
Headache    
Blurred vision    
Fatigue    
Weakness    
Dizziness    
Lightheadedness    
Syncope (sudden loss of consciousness)    
Sleeping difficulties    
Increased acne    
Other    
If yes to other, please specify:
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via 17OHP and androstenedione. Because patients had 
differing exposure to MR-HC before the study start, as-
sessment was made against a pre–MR-HC baseline.
Statistical Analysis
The trial was designed to have greater than 95% power, 
at a 2-sided α of 5%, to detect a difference between treat-
ment groups in the primary outcome consistent with the 
phase  2 study results. The primary outcome was com-
pared between treatment groups within an analysis of co-
variance linear model with prestudy treatment category 
and baseline mean SDS as covariates. The same model 
was used for secondary and exploratory analyses of SDS 
and the area under the 24-hour profiles curve (AUC). 
Variability (amplitude) within a 24-hour hormone profile 
was defined as the maximum value divided by the min-
imum value. The change in the amplitude between base-
line and 24 weeks, expressed as a ratio, was compared 
between treatment groups using a Wilcoxon test. The 
proportion of patients with good disease control at 24 
weeks (09:00h 17OHP < 1200 ng/dL) was compared be-
tween treatment groups using a logistic model, adjusting 
for good disease control at baseline. All P values are 
2-tailed and all CIs are 95% 2-sided. Because all partici-
pants in the extension trial received MR-HC, there were 
no formal treatment comparisons, but summaries over 
time were produced for safety and efficacy parameters.
Safety
Adverse events were recorded, including adverse events of 
special interest such as adrenal crisis. Events of therapeutic 
benefit such as restoration of menstruation have been re-
corded using the MedDRA term “unexpected therapeutic 
benefit” as recommended by regulators.
Results
Patients
In the phase 3 study, 138 patients were screened, 122 were 
randomly assigned, 117 completed the study, and 105 met 
the criteria for efficacy analysis (Fig. 1). Between 3 and 25 
patients were recruited from each European center, with 8 
from the US center. Overall, the 2 treatment groups were 
balanced (see Table 1), but the number of patients with 
good baseline disease control was higher in the standard 
group. At baseline, 84% of patients were taking standard 
glucocorticoids after 18:00h, and 84% of patients were 
diagnosed as salt-wasting (see Table 1). Five patients (3 
MR-HC, 2 standard) had experienced an adrenal crisis 
in the preceding year. In the extension study, 91 pa-
tients received at least one dose of MR-HC and 83 were 
participating at the time of this data cut (see Fig. 1). Safety 
data are presented up to 2  years and biochemical up to 
18  months. Patients who chose not to participate in the 
extension study did so predominantly from one center be-
cause of logistical reasons (n = 13). Withdrawals were pri-
marily for practical reasons, including desire for pregnancy.
Biochemical Disease Control
In phase 3, both groups achieved better hormonal control 
at 24 weeks compared to baseline reflected by a negative 
change in the 17OHP SDS 24-hour profile, therefore the 
trial failed its primary outcome (P = .55) (Table 3). There 
was no statistical difference between any of the groups, 
and removing any of the groups from the analysis did not 
change the primary outcome. The change from baseline was 
greater in MR-HC group at 4 (P = .007) and 12 (P = .019) 
weeks. At 24 weeks, a greater reduction in the 17OHP SDS 
profile was observed in the MR-HC group compared to the 
standard group between 07:00h and 15:00h (P = .044), and 
a reduction in the 17OHP AUC occurred in both groups, 
with a greater reduction in the MR-HC group (P = .025). 
At 24 weeks, compared to the standard group, good disease 
control (17OHP < 1200  ng/dL at 09:00h) was achieved 
more often in the MR-HC group (90.6% vs 71.2%, 
P = .002) and 17OHP variability (amplitude) over 24 hours 
was reduced in the MR-HC group (P < .001). At baseline 
the group randomly assigned to continue on standard treat-
ment was better controlled than the MR-HC group 32/52 
(62%) vs 20/53 (38%), and after 24 weeks 28 of 33 (85%) 
of those not under control at baseline were controlled in 
the MR-HC group, with 10 and 20 (50%) in the standard 
treatment group. The androstenedione SDS profile and 
change in AUC was similar to that for 17OHP. The pattern 
of biochemical control displayed in the 24-hour profiles 
differed between the 2 groups (Fig. 2). At 24 weeks, the 
MR-HC group 24-hour profile flattened and normalized 
both for 17OHP (Fig. 2A) and androstenedione (Fig. 2B), 
whereas the pathological morning increase in adrenal an-
drogen precursors persisted in the standard group (Fig. 
2C and 2D). Thus, a difference between the 2 groups at 
week 24 was observed during the morning hours, but not 
throughout the day (Fig. 2E and 2F). In the extension study, 
the number of patients in good disease control for 17OHP 
at 09:00h was 80% at 18 months vs 52% at baseline (Fig. 
2G, Tables 1 and 3) and for androstenedione 96% vs 45% 
at baseline. In the phase 3 study, it did not make a differ-
ence to the analysis whether good control was measured at 
either 0700h or 0900h, so we used 0900h in the extension 
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Daily Glucocorticoid and Mineralocorticoid Dose
At 24 weeks, the MR-HC group increased from a median 
dose of 25 mg to 30 mg and standard glucocorticoid from 
25  mg to 31  mg hydrocortisone dose equivalent (Table 
4). Overall and by type of glucocorticoid at baseline, the 
MR-HC and standard groups were receiving similar gluco-
corticoid doses, but more patients required uptitrations in the 
standard group (31 vs 28) and more required downtitrations 
in MR-HC group (13 vs 3). The dose of fludrocortisone was 
changed in 3 patients (2 MR-HC and 1 standard). In the 
extension study, patients were downtitrated and the median 
dose at 18 months was 20 mg (see Table 4).
There was no statistical difference between participants 
on the different standard treatment regimens at baseline, 
and removing any of the groups from the analysis did not 
change the primary outcome. In the prednisolone/pred-
nisone at baseline patient group, the hydrocortisone dose 
on MR-HC fell from a median of 30  mg at baseline to 
27.5  mg at 24 weeks and for those who continued on 
prednisolone, the hydrocortisone dose equivalent in-
creased from 26.6 mg to 32.8 mg. There were relatively 
few patients on dexamethasone at baseline (n = 10) and 
they were split into those continuing dexamethasone 
(n = 5) and those who transferred to MR-HC (n = 5). For 
the patients who were on dexamethasone at baseline, the 
median dose in hydrocortisone equivalents of dexametha-
sone and MR-HC did not change from baseline to 24 
weeks.
Secondary Outcomes of Interest
No differences between the 2 treatment groups were seen for 
fat mass, lean mass, or bone mineral density by DEXA; bone 
markers (serum C-terminal telopeptide and fasting osteocalcin); 
laboratory assessments of interest including high-sensitivity 
C-reactive protein, fasting glucose, fasting insulin, homeostatic 
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model assessment of insulin resistance, glycated hemoglobin A
1c
, 
total testosterone, and plasma renin activity (Table 5). No sig-
nificant changes in QoL were seen although responses for the 
majority of domains improved (Table 6).
Safety
In this phase 3 study, no patients experienced adrenal crises in 
the MR-HC group compared with 3 (4.9%) in the standard 
group. A  total of 299 adverse events (15 of therapeutic 
benefit) were reported by 96.7% of patients in the MR-HC 
group, and 224 adverse events (1 of therapeutic benefit) were 
reported by 78.7% of patients in the standard group. No ser-
ious adverse event was considered causally related to study 
intervention. Glucocorticoid stress dosing was reported by 
26 patients (42.6%) in the MR-HC group and 36 patients 
(59.0%) in the standard group. Unexpected events con-
sidered to be of therapeutic benefit included resumption of 
Table 3. Study outcomes and disease-relevant clinical eventsa
MR-HC group Standard group Comparison between groups
Biochemical outcomes from phase 3 N = 53 N = 52 Treatment effectb (95% CI), Pc
 Baseline natural log 17OHP SDS profile 1.25 ± 0.73 1.03 ± 0.82  
 Change from baseline in natural log 17OHP SDS profile    
  24-h profile at 4 wks –0.37 ± 0.63 –0.07 ± 0.42 –0.26 (–0.46 to –0.07), P = .007
  24-h profile at 12 wks –0.52 ± 0.85 –0.10 ± 0.67 –0.30 (–0.54 to –0.05), P = .019
 Primary end point: 24-h profile at 24 wks –0.40 ± 0.85 –0.17 ± 0.78 –0.07 (–0.30 to 0.16), P = .55
  07:00h-15:00h profile at 24 wks –0.69 ± 0.96 –0.21 ± 0.79 –0.29 (–0.56 to –0.01), P = .044
 Baseline natural log 17OHP 24-h AUC 65.2 ± 38.5 54.0 ± 39.2  
 Change from baseline in natural log 17OHP 24-h AUC    
  24-h profile at 4 wks –23.9 ± 27.7 –6.1 ± 19.3 –16.6 (–25.5 to –7.8), P < .001
  24-h profile at 12 wks –35.5 ± 35.3 –13.5 ± 28.5 –17.8 (–29.0 to –6.6), P = .002
  24-h profile at 24 wks –37.7 ± 42.6 –17.8 ± 29.0 –13.8 (–25.8 to –1.8), P = .025
 Amplitude ratio of 17OHPd: median (95% nonparametric CI]) 0.36 [0.24, 0.65] 0.92 [0.77, 1.37] 0.38 (0.24, 0.61), P < .001
 Baseline natural log androstenedione 24-h AUC 21.4 ± 30.4 13.9 ± 32.2  
 Change from baseline in natural log androstenedione 24-h AUC    
  24-h profile at 4 wks –12.5 ± 22.2 –3.1 ± 11.3 –8.9 (–15.6 to –2.1), P = .011
  24-h profile at 12 wks –20.6 ± 23.8 –8.0 ± 15.1 –10.9 (–18.3 to –3.5), P = .004
  24-h profile at 24 wks –22.9 ± 26.9 –9.3 ± 20.4 –10.5 (–18.7 to –2.3), P = .013
Disease-relevant clinical events phase 3 study N = 61 N = 61  
  Adrenal crises, No. of patients (%) 0 (0) 3 (5.8) NA
  Stress dosing, No. of patients (%) 26 (49.1) 36 (69.2) NA
  Restoration of menses, No. of patients (%) 4 (7.5) 1 (1.9) NA
  Partner pregnancy (%) 2 (3.8) 0 (0) NA
Biochemical outcomes from extension study (N = 50)   
 Good disease controle (17OHP) at 18 mos, No. of patients (%) 40 (80.0) – NA
 17OHP suppressed, No. of patients (%)↓ 2 (4.0) – NA
Disease-relevant clinical events phase 3 study (N = 91)   
 Adrenal crises, No. of patients (%) 4 (4.4) – NA
 Stress dosing, No. of patients (%) 72 (79.1) – NA
 Restoration of menses, No. of patients 4 (4.4) – NA
 Patient pregnancy 3 (3.3) – NA
 Partner pregnancy 2 (2.2) – NA
↓Suppressed 17OHP defined as undetectable.
Abbreviations: 17OHP, 17-hydroxyprogesterone; AUC, area under the curve; GC, glucocorticoid; MR-HC, modified-release hydrocortisone; NA, not available; 
SDS, SD score.
aPlus-minus values are means ± SD.
bTreatment effect is defined as least-squares mean difference (MR-HC – standard GC) for SDS profiles and 24-hour AUC adjusted for baseline value and prebaseline 
therapy, as the ratio MR-HC to standard GC for amplitude ratio, and as the odds ratio MR-HC vs standard GC for good disease control adjusted for baseline 
disease control status.
cCIs and P values were obtained from an analysis of covariance model for SDS profiles and 24-hour AUC, by the Hodges-Lehmann, and Wilcoxon methods, re-
spectively, for amplitude ratio, and from a logistic model for good disease control.
dAmplitude is defined as the maximum divided by the minimum over the 24-hour assessment period. The ratio is the amplitude at 24 weeks divided by the am-
plitude at baseline.
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regular menses in 5 patients (4 MR-HC, 1 standard), partner 
pregnancies of 2 patients in the MR-HC group with full-term 
deliveries; one of these patients had a history of testicular 
adrenal rest tissue with documented sperm count improve-
ment (< 0.1 million/mL prior to MR-HC and 10.3 million/
mL during MR-HC treatment).
Figure 2. Twenty-four–hour endocrine profiles for 17-hydroxyprogesterone (17OHP) and androstenedione at week 24 vs baseline (geometric 
mean ± 95% CIs, patients meeting the criteria for the efficacy analysis) and 09:00hrs 17OHP during the extension study. A, At week 24, the 17OHP 
24-hour profile for patients receiving modified-release hydrocortisone (MR-HC) was flat, and the morning rise in 17OHP observed at baseline was no 
longer present. B, Similar results were observed for androstenedione. Patients in the standard glucocorticoid group had improvement in hormonal 
control with glucocorticoid dose adjustments according to the protocol, but the pattern of hormone secretion did not change: C, 17OHP, and D, andro-
stenedione, profiles continued to display a morning increase. At week 24, the MR-HC vs standard groups differed during the morning hours but not 
throughout the 24 hours for E, 17OHP, and F, androstenedione. G, During the extension study, the geometric mean 09:00h 17OHP fell from baseline 
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In the extension study there were 4 patients with ad-
renal crises. A  total of 780  adverse events (29 of thera-
peutic benefit) were reported by 87 participants (95.6%). 
Severe adverse events were reported for 14 participants 
(15.4%), of which one was considered related to MR-HC 
(hypokalemia). Glucocorticoid stress dosing was reported 
for 72 participants (79.1%). The most common (18 pa-
tients, 19.8%) reported events considered to be of thera-
peutic benefit were feeling more alert (11 patients) and 
improved menstrual cycle (4 patients). The partner of 2 
patients on MR-HC became pregnant during the study and 
successfully delivered. Three patients became pregnant on 
MR-HC; one suffered an early miscarriage after transi-
tioning to standard therapy.
Discussion
This is the first randomized, controlled trial of gluco-
corticoid treatment in patients with 21-OHD-CAH. 
Patients who received MR-HC had superior hormonal 
control during the morning and early afternoon compared 
to those receiving standard therapy, and this was sustained 
over 18 months of follow-up. Morning hormonal control 
is important in 21-OHD-CAH because failure to control 
the overnight increase in adrenal androgens results in ex-
cess glucocorticoid exposure and poor health outcomes 
(5). The trial failed its primary end point because the differ-
ence between the 2 groups in the morning did not translate 
into a difference over 24 hours at 24 weeks. The primary 
outcome was based on a phase 2 trial (19); however, the 
analysis was unhelpful in the phase 3 randomized trial be-
cause the SDS analysis overemphasized scores below the 
midpoint of the reference range, and the logarithmic trans-
formation and use of a mean score over 24 hours obscured 
the impact of MR-HC in the morning and early afternoon. 
The raw data showed significant improvement of the clin-
ically relevant end point of morning biochemical control, 
with reduced AUC and 17OHP amplitude in patients re-
ceiving MR-HC. The improvement in biochemical con-
trol was maintained at 18 months, with 80% displaying 
good control for 17OHP and 96% for androstenedione 
vs 52% and 45% at baseline, despite reduction of the 
Table 4. Glucocorticoid doses at baseline, 24 weeks, and during the extension study
Dose MR-HC group Standard  
glucocorticoid groupa
Baseline 24 wks Baseline 24 wks
All (hydrocortisone dose equivalents)b     
 Median daily dose, mg 25.0 30.0 25.0 31.3
 Range 15-50 10-65 12.5-80 12.5-80
 Median dose/BSA, mg/m2/d 13.6 15.8 14.4 17.0
On hydrocortisone at baseline     
 Median daily dose, mg 20.0 25.0 23.75 25.0
 Range 12.5-40 10-65 12.5-35 15-55
 Median dose/BSA, mg/m2/d 12.0 15.1 12.3 14.5
On prednis(ol)one at baseline     
 Median daily dose, mg 30 27.5 26.6 32.8
 Median dose/BSA, mg/m2/d 16.7 16.5 15.7 18.5
 Range 12.5-50 15-50 12.5-50 12.5-50
On dexamethasone at baseline     
 Median daily dose, mg 30 30 40 40
 Range 29.6-38 30-45 20-80 33.5-80
 Median dose/BSA, mg/m2/d 17.3 17.3 17.5 20.6
MR-HC Safety Extension Study
Time from study start 0-4 wks 4-12 wks 12-24 wks 6-12 mos 12-18 mos 18-24 mos
MR-HC MR-HC MR-HC MR-HC MR-HC MR-HC
Median daily dose, mg, MR-HC 30 26.0 25.0 20.3 20.1 20.0
Range 10-55 10-55 10-55 10-50.3 10-50.3 7.3-55
Median dose, mg/m2/d, MR-HC 15.8 15.0 13.5 12.5 11.7 11.1
No. of patients with data available 91 91 88 87 74 50
Abbreviations: BSA, body surface area; MR-HC, modified-release hydrocortisone.
aStandard glucocorticoid group are patients who continued on their conventional prestudy glucocorticoid treatment.
bConversion factors established in endocrinology were used: Prednisone/prednisolone dose was multiplied by 5, and dexamethasone dose was multiplied by 80 (11). 



































































































































Table 5. Secondary outcomes and vital signs at baseline and change at 24 weeks and at 2 years in the extension study
Outcome MR-HC group baseline and change at 24 wks Standard glucocorticoid group baseline and 
change at 24 wks
Extension study MR-HC baseline and 
change at 18-24 mos
Safety set N = 61 N = 61 N = 50
Baseline Change Baseline Change Baselinea Change
Weight, kg 75.5 (18.5) 0.87 (3.7) 74.6 (13.2) 1.0 (2.7) 75.6 (16.1) –0.28 (4.8)
Body mass index, kg/m2 28.5 (6.4) 0.3 (1.5) 27.7 (4.3) 0.4 (1.0) 28.8 (5.7) –0.08 (2.0)
Waist circumference, cm 90.9 (16.3) 0.2 (5.4) 90.5 (11.8) 1.0 (5.6) 91.5 (14.8) 0.69(5.7)
Systolic blood pressure, mm Hg 120.9 (13.6) -1.8 (11.4) 120.2 (14.4) 0.5 (11.2) 120.4 (13.9) –3.1 (10.4)
Diastolic blood pressure, mm Hg 71.1 (10.6) -0.5 (9.2) 70.6 (11.0) 0.2 (9.2) 70.6 (10.8) –0.4 (9.4)
Efficacy evaluable set N = 53 N = 52 N = 50
Fat mass, kg 29.535 (11.7) –0.575 (3.3) 26.163 (10.3) 0.445 (2.5) 27.943 (11.5) –0.718 (4.8)
Lean mass, kg 46.975 (9.3) 0.640 (2.3) 45.468 (9.1) 0.234 (1.4) 45.819 (9.3) –0.079 (3.4)
Bone mineral density, g/cm2 1.126 (0.1) –0.001 (0.0) 1.111 (0.1) –0.008 (0.0) 1.094 (0.092) 0.001 (0.04)
C-terminal cross-linked telopeptide, ng/L 570 (257) 9.3 (161) 590 (260) –23.3 (120) 540.1 (252) –52.3(176)
Fasting osteocalcin, μg/L 19.93 (8.4) –0.6 (8.1) 21.51 (10.0) –2.1 (6.3) 19.49 (7.9) 4.4 (8.2)
hsCRP, mg/L 1.38 (1.3) 0.54 (2.6) 2.04 (4.4) 0.20 (7.5) 1.78 (5.0) 2.3 (6.2)
Fasting glucose, mg/dL 92.1 (8.5) 9.9 (10.2) 90.1 (9.9) 1.8 (8.8) 91.7 (7.8) 2.6 (9.8)
Fasting insulin, mIU/L 12.6 (6.3) 1.9 (6.8) 11.7 (5.6) 3.0 (7.4) 13.0 (5.9) –2.1 (6.3)
HOMA-IR 2.894 (1.6) 0.914 (2.1) 2.59 (1.3) 0.77 (1.8) – –
HbA
1c
 (%) 5.16 (0.28) 0.02 (0.26) 5.18 (0.43) –0.02 (0.28) 5.17 (0.31) 0.12 (0.23)
Plasma renin activity, ng/mL/h 3.5 (2.5) –1.0 (2.4) 2.9 (2.4) 0.4 (2.5) 3.2 (3.5) –0.2 (0.9)
Total testosterone women, ng/dL 33 (33.4) -21 (127.8) 32 (52.9) –9 (30.4) 147 (263.8) –13 (63.4)






; HOMA-IR, homeostatic model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; MR-HC, modified-release hydrocortisone.
aBaseline in extension study is pre–MR-HC.
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hydrocortisone dose by 33%, to doses regularly used for 
adrenal replacement therapy.
MR-HC replicates the physiological overnight increase 
in cortisol, thereby preventing ACTH-driven excess pro-
duction of adrenal androgens (19). MR-HC given twice 
daily replicates both the early morning increase in cor-
tisol as well as daytime cortisol levels (22). There is some 
evidence that cortisol clearance may vary over 24 hours, 
possibly related to a circadian rhythm in cortisol-binding 
protein; however, the amplitude of this variation is small 
and does not appear clinically significant (23). Biochemical 
control was better on MR-HC compared to standard 
glucocorticoid at 4 weeks (ie, prior to dose titration) when 
patients were receiving MR-HC at an equivalent daily dose 
to baseline treatment. At 24 weeks, following dose titra-
tion, morning control was better on MR-HC than standard 
glucocorticoids, 91% in control vs 71%, respectively, with 
little fluctuation in 17OHP and no morning increase in the 
MR-HC–treated patients, similar to the profile of 17OHP 
in normal physiology. These findings are important because 
it is the high excursions in 17OHP that drive production 
of androstenedione and androgens that affect growth, pu-
berty, and fertility.
Immediate-release hydrocortisone is the recommended 
first-line therapy in 21-OHD-CAH; prednisolone and 
dexamethasone are introduced when biochemical control 
cannot be achieved, but are associated with higher rates of 
adverse outcomes (15, 24, 25). Higher bedtime doses (re-
verse circadian regimen) are commonly used in an attempt 
to improve androgen control (11, 26, 27), with 84% at 
baseline in this study; however, evening glucocorticoid ad-
ministration has the potential for adverse metabolic actions 
(28) and insomnia. The median hydrocortisone dose at 24 
weeks was 15.8 and 17.0 mg/m2/day for MR-HC and the 
standard group, respectively, similar doses to those reported 
in cohort studies (15-18 mg/m2/day), in which biochemical 
control was worse than in this trial (10, 11, 29, 30). In the 
extension study, with local clinicians performing dose ti-
trations, biochemical control was maintained at a reduced 
daily dose of 20 mg consistent with that recommended for 
replacement in adrenal insufficiency: 15 to 25  mg daily 
(31). On study entry the patients had their therapy opti-
mized for 6 months, and yet were able to have a sustained 
dose reduction in the extension study. Optimal control 
of adrenal androgens is required for fertility in men and 
women with 21-OHD-CAH (32-34). Our findings demon-
strate clinical value for improved morning hormonal con-
trol, with women restarting menstruation, improved sperm 
quality in a patient with testicular adrenal rest tissue, and 4 
partner and 3 patient pregnancies on MR-HC.
There are few published data on the circadian variation 
of 17OHP in healthy individuals, but what there is demon-
strate that in the normal individual 17OHP displays minor 
circadian variability within the reference range and varies 
Table 6. Quality of life assessments at 24 weeks (phase 3 study) and at 12 and 18 months (extension study)
Parameter Phase 3 study Safety extension study
MR-HC groupN = 53 Standard groupN = 52 12 mosN = 73 18 mosN = 51
SF-36 absolute change from baseline by domaina
T score: bodily painb NA NA NA NA
T score: general health perceptions 0.79 (7.54) –1.88 (5.97) 1.43 (8.76) 2.11 (5.66)
T score: mental health 0.86 (7.32) 0.35 (7.81) 1.49 (9.44) 1.33 (6.89)
T score: physical functioning 1.16 (6.43) -0.52 (4.27) 0.41 (4.38) 0.28 (4.25)
T score: role emotional 0.99 (9.95) -0.34 (9.21) 1.38 (11.65) 0.48 (8.50)
T score: role physical 1.91 (8.33) 0.50 (6.68) 1.42 (7.53) 0.81 (9.24)
T score: social functioning 2.18 (9.25) 0.87 (6.86) 2.54 (9.00) 0.89 (8.95)
T score: vitality 0.79 (9.45) 0.92 (6.10) 2.15 (8.44) 2.56 (6.80)
Global Fatigue Index absolute change in score from baseline
GFI score derived from MAF –0.74 (11.1) –0.26 (7.8) –1.93 (10.1) –2.31 (10.6)
EQ-5D summary changes from baseline
EQ-5D VAS score –1.3 (13.67) –1.2 (12.62) 2.7 (17.74) 2.3 (12.33)
EQ-5D-5L index score 0.02 (0.12) 0.02 (0.14) –0.01 (0.17) –0.01 (0.14)
Values are mean (SD).
GFI scores range from 1 (no fatigue) to 50 (severe fatigue).
Abbreviations: EQ-5D, Standardized Health Questionnaire (5L = 5-level); GFI, Global Fatigue Index; MAF, multidimensional assessment of fatigue; MR-HC, 
modified-release hydrocortisone; N, number of evaluable participants; NA, not available; SF-36, Medical Outcome Short Form Health Survey Form 36 (Subject 
Questionnaire); VAS, visual analog scale.
aBaseline is defined as start of study in the phase 3 study and pre–MR-HC initiation baseline in the safety extension study.
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by the phase of the menstrual cycle in females (35, 36). The 
reference range for 17OHP at the Mayo Clinic is less than 
285  ng/dL during the luteal phase, which is the highest 
level seen in healthy individuals. Clinicians have recognized 
that in patients with CAH receiving standard therapy, it is 
not possible to control 17OHP in the morning even when 
raising the dose of glucocorticoid. This is shown in the pre-
sent study in patients on standard treatment whose gluco-
corticoid dose was increased. To avoid overtreatment, 
guidelines have suggested not suppressing the 17OHP into 
the reference range, and 2 observational cohort studies of 
CAH defined an optimal range of 17OHP to be less than 
1200 ng/dL, which approximates to 3 times the upper limit 
of the normal range (10, 11). Our phase 3 study shows that 
by treating with MR-HC, which provides a physiological 
increase in cortisol levels overnight, it is now possible to 
control the overnight increase in 17OHP so a relatively flat 
17OHP profile over 24 hours is achieved, similar to that 
seen in healthy individuals. In the phase 3 study, we found 
that MR-HC at 30 mg per day controls many patients into 
the reference range and this dose is similar to that reported 
in all 4 CAH cohort studies in which dose is provided and 
control is generally less than 50% (10, 11, 29, 30). When 
the dose of MR-HC was reduced in the extension study to 
adrenal replacement levels, median dose 20 mg, the 17OHP 
remained in the optimal range in 80% of patients. This me-
dian dose is 20% to 40% less (5-10 mg/day less) than that 
reported in the cohort studies (10, 11, 29, 30). The “op-
timal” 17OHP level could be debated and practices vary 
among clinicians; however, there is agreement that lower 
glucocorticoid doses are beneficial and this was achieved 
in the extension study, with female patients reporting im-
provements in menstrual regularity and improvement in 
fertility in both sexes.
The evidence that an adrenal replacement dose of 
hydrocortisone has better health outcomes than the 
higher doses more commonly used in CAH comes from 
the literature examining hydrocortisone replacement 
therapy in adrenal insufficiency. In large retrospective 
studies of patients on glucocorticoids, a hydrocortisone 
equivalent dose greater than 20 mg per day was associ-
ated with an unfavorable metabolic profile (37), and a 
daily dose of hydrocortisone greater than 25 mg per day 
was associated with increased mortality (38). Similarly, 
higher replacement doses of hydrocortisone have been 
associated with lower QoL in patients with adrenal in-
sufficiency (39), and lower psychological well-being (40). 
In a large longitudinal historical cohort study in pedi-
atric patients, the dose of hydrocortisone in patients with 
CAH was negatively associated with final height, with 
each 1 mg/m2/day of hydrocortisone equating to a loss of 
0.37 cm in height (41).
Currently there is no consensus on monitoring gluco-
corticoid therapy in CAH (10). Clinicians measure bio-
markers before and after dosing (42), and aim for 17OHP 
levels above the reference range and androstenedione 
within the reference range for good control, with normal 
17OHP indicating overtreatment and high androstene-
dione indicating undertreatment (14, 24). In 21-OHD-
CAH, the physiological pathway to androstenedione 
biosynthesis from 17-hydroxypregenolone via DHEA 
(dehydroepiandrosterone) is downregulated (42, 43), and 
androstenedione biosynthesis primarily occurs through 
conversion of excess 17OHP. With MR-HC treatment, we 
observed near normalization of 17OHP and concurrently 
low androstenedione, despite a median daily MR-HC dose 
of 20 mg, suggesting that the low androstenedione is not 
explained by glucocorticoid-mediated suppression. Thus, 
you cannot keep downtitrating the glucocorticoid dose 
based on a low A4 because you will go below adrenal re-
placement doses and risk adrenal insufficiency. The mode 
of action of MR-HC flattens the 24-hour 17OHP profile, 
similar to that seen in healthy individuals, and provides 
the rationale for a monitoring and titration schedule 
whereby the morning 17OHP reflects the evening dose 
and the afternoon 17OHP the morning dose of MR-HC. 
Thus, in the extension study, patients have been titrated 
using a sample measured at 0900h and 1300h, which are 
times suitable for the clinic. Two samples are required 
and could potentially be provided remotely if suitable 
validated assays for saliva and blood spot are available. 
MR-HC provides a potential simplified paradigm for the 
treatment and monitoring of CAH with dosing at bed-
time and waking, and hormonal measurements at 0900h 
to judge the nighttime dose and around midday to judge 
the morning dose.
The lack of significant differences in clinical and 
patient-reported outcomes between the 2 groups in the 
phase  3 study reflects the study’s short duration and 
similar daily glucocorticoid doses. QoL has been shown 
to improve when using a pump to deliver subcutaneous 
diurnal hydrocortisone infusion to 21-OHD-CAH pa-
tients with poor control and QoL at baseline (17); how-
ever, QoL in 21-OHD-CAH has variably been reported 
as either impaired or normal (44). Our patients were a 
diverse population at baseline with a QoL similar to the 
general population, which would make demonstrating im-
provement difficult.
More than one-third of patients had an infection during 
the study, consistent with the observation that patients with 
adrenal insufficiency have higher infection rates (45), and em-
phasizes the importance of teaching patients sick day rules. 
Mortality in patients with 21-OHD-CAH is increased and 
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(8, 9). The incidence of adrenal crisis in patients with adrenal 
insufficiency is estimated to be 5 to 10 adrenal crises/100 
patient-years, with a mortality rate of 0.5/100 patient-years 
(20, 21, 46–48). Five of 122 patients had an adrenal crisis in 
the year before the study (3 randomly assigned to MR-HC), 
and during the randomized study, 3 patients in the standard 
group had an adrenal crisis but none did in the MR-HC 
group. In the extension study, 4 patients had an adrenal crisis 
with a frequency of 6.2 crises per 100 treatment-years, similar 
to population estimates (20, 48), and providing confidence 
that the safety profile of MR-HC does not differ from that of 
immediate-release hydrocortisone.
A strength of our phase 3 study was its international, 
multicenter, randomized design enabling us to study a 
large cohort in a rare disease; the extension study provided 
data on up to 2 years of treatment with MR-HC, a sound 
basis for efficacy and safety assessment. The limitations of 
the phase 3 study include its open-label design (mitigated 
by the blinded dose titration) and the complexity of the 
protocol and statistical analysis. Blinding was considered 
impractical because of the multiple dosing regimens and 
the difficulties replicating the bitterness of hydrocorti-
sone in a placebo. It was challenging to admit patients 
for a 24-hour profile, which may have restricted recruit-
ment and created a selection bias for better-controlled pa-
tients. The intensive monitoring and more aggressive dose 
uptitration than usually performed in clinical practice 
may explain the improved control in the standard group 
compared to previous observational studies of 21-OHD-
CAH (10, 11), and the extension study demonstrated that 
MR-HC dose reduction could be achieved with more 
simplified monitoring.
In conclusion, we found that MR-HC improved morning 
and early afternoon biochemical control of 21-OHD-CAH 
over standard glucocorticoid therapy. This control was 
sustained for 18 months on hydrocortisone doses recom-
mended for adrenal replacement therapy and lower than 
doses normally used in 21-OHD-CAH. MR-HC provides a 
well-tolerated and practical twice-daily treatment regimen 
for 21-OHD-CAH.
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